文献速递腹部USMR

CEUS LI-RADS TRA v2024用于TACE后肝内转移早期评估的可行性

Feasibility of CEUS LI-RADS Nonradiation Treatment Response Assessment for Early Evaluation of Intrahepatic Metastases After TACE.
PubMed 文献 · Acad Radiol · 2026-09-14

本前瞻性研究纳入38例接受TACE的肝内转移患者,于术后1-2个月行超声及CEUS检查,按CEUS LI-RADS TRA v2024进行独立双阅片,并以增强MRI为参考标准。结果显示该标准可重复性达显著至优秀水平,单独病灶内增强可提供最均衡的诊断效能。联合病灶周围增强或常规超声征象未提高总体诊断效能,且可能降低诊断明确性。

要点

  • TACE术后1-2个月内单看CEUS病灶内增强最可靠,不建议常规联合周围增强判读。
  • 病灶内增强在双阅片中重复性最高,且诊断敏感度、特异度与准确率最为均衡。
  • 联合病灶周围增强或常规超声变化会提高敏感度与NPV,但常以特异度下降和不确定病例增多为代价。

核心结论

  • CEUS LI-RADS TRA v2024对TACE术后早期肝内转移评估具有可行性和可重复性。
  • 在术后1-2个月内,单独依据病灶内增强具有最均衡的诊断效能和可重复性。
  • 增加病灶周围增强及常规超声征象未提升总体诊断效能,并可能降低诊断清晰度。

研究设计与样本

  • 前瞻性研究,纳入38例接受TACE治疗的肝内转移患者,平均年龄64岁(41-89岁)。
  • TACE前及术后1-2个月内行常规超声和CEUS,以增强MRI作为参考标准。
  • 两名阅片者依据CEUS LI-RADS TRA v2024独立评估,采用Cohen κ和ICC评估观察者间一致性。
  • 比较单独病灶内增强与联合病灶周围增强、常规超声特征等多种评估策略。

关键影像表现/征象

  • TACE术后病灶回声、边界、病灶内增强及病灶周围增强较术前出现显著变化(均P<0.05)。
  • CEUS LI-RADS TRA v2024征象的观察者间一致性为显著至优秀,κ为0.78-0.87,ICC为0.69-0.96。
  • 病灶内增强的一致性最高(κ=0.87,ICC=0.96),且两位阅片者均保持最佳总体诊断效能。
  • 联合病灶周围增强后不确定病例由2.6%-10.5%增至15.8%-23.7%,诊断明确性下降。

诊断标准与关键数值

  • 单独病灶内增强:敏感度93.3%-96.7%(95%CI 77.9-99.9),特异度75.0%-87.5%(95%CI 34.9-99.7),准确率89.5%-94.7%(95%CI 75.2-99.4),PPV 100.0%(95%CI 87.7-100.0),NPV 87.5%-100.0%(95%CI 47.3-100.0),不确定病例占2.6%-10.5%。
  • 联合病灶周围增强后敏感度升至93.3%-100.0%,NPV达100.0%,但特异度降至12.5%-25.0%,准确率降至76.3%-84.2%,不确定病例占15.8%-23.7%。
  • 病灶内增强联合回声变化、边界变化及周围增强后NPV均达100.0%,但总体诊断效能未提高甚至部分下降。
  • 联合策略敏感度96.7%-100.0%,特异度37.5%-75.0%,准确率84.2%-94.7%,PPV 88.2%-100.0%,不确定病例0.0%-15.8%。

临床应用与阅片要点

  • TACE术后1-2个月进行CEUS疗效评估时,可优先以病灶内增强模式作为主要判读依据。
  • 不建议常规将病灶周围增强纳入早期疗效判读,因为会增加不确定病例并降低诊断明确性。
  • 常规超声所示病灶回声与边界变化可作为辅助观察,但联合判读未提高总体诊断效能。

局限性

  • 单中心前瞻性研究,样本量仅38例。
  • 参考标准为增强MRI而非病理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To explore the feasibility and reproducibility of applying contrast-enhanced ultrasound liver imaging reporting and data system nonradiation treatment response (CEUS LI-RADS TRA v2024) criteria for assessing intrahepatic metastases within 2 months after transarterial chemoembolization (TACE).

MATERIALS AND METHODS: In this prospective study, 38 patients (mean age, 64 years; range, 41-89 years) with intrahepatic metastases undergoing TACE were included. US and CEUS were performed before and after TACE treatment, with a follow-up duration of 1-2 months. Imaging features, including treated lesion (TL) size, shape, echogenicity, margin, and perilesional echogenicity, were evaluated based on interval changes before and after TACE on conventional B-mode US, along with intralesional and perilesional enhancement patterns on CEUS. CEUS findings were independently evaluated by two readers according to CEUS LI-RADS TRA v2024. Interobserver agreement was assessed using Cohen's kappa and intraclass correlation coefficient (ICC). Multiple assessment strategies were compared based on intralesional enhancement alone and in combination with perilesional enhancement and conventional US features. Diagnostic performance was assessed using sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV), as well as the proportion of indeterminate cases. Statistical analyses were performed using Fisher's exact test, independent samples t-test, and Mann-Whitney U test, and receiver operating characteristic (ROC) curve analysis to determine optimal cutoff values. The reference standard was based on contrast-enhanced magnetic resonance imaging (CEMRI).

RESULTS: Significant post-treatment changes were observed in TL echogenicity, margin, intralesional enhancement, and perilesional enhancement (all P < 0.05). Interobserver agreement for LI-RADS TRA v2024 CEUS features was substantial to excellent, with κ values ranging from 0.78 to 0.87 and ICC values ranging from 0.69 to 0.96 (all p < 0.001). Intralesional enhancement demonstrated the highest reproducibility (κ = 0.87, ICC = 0.96) while maintaining the best overall diagnostic performance across both readers, with sensitivity of 93.3-96.7% [95% Confidence Interval (CI):77.9-99.9], specificity of 75.0-87.5% (95% CI:34.9-99.7), accuracy of 89.5-94.7% (95% CI:75.2-99.4), PPV of 100.0% (95% CI:87.7-100.0), NPV of 87.5-100.0% (95% CI: 47.3-100.0), and only 2.6%-10.5% indeterminate cases. The addition of perilesional enhancement increased sensitivity (93.3%-100.0%) and NPV (100.0%) but reduced specificity (12.5%-25.0%), accuracy (76.3-84.2%), and diagnostic clarity, resulting in 15.8-23.7% cases deemed equivocal. When intralesional CEUS features were further combined with changes in TL echogenicity, TL margin, and perilesional enhancement before and after TACE, NPV consistently reached 100.0%, but overall diagnostic performance did not improve and in some cases decreased, with sensitivity ranging from 96.7% to 100.0%, specificity from 37.5% to 75.0%, accuracy from 84.2% to 94.7%, PPV from 88.2% to 100.0%, and indeterminate cases ranging from 0.0% to 15.8%. Notably, the inclusion of perilesional enhancement substantially increased the number of equivocal cases, indicating that additional imaging features increased sensitivity at the expense of diagnostic specificity and clarity.

CONCLUSION: CEUS LI-RADS TRA v2024 is feasible and reproducible for early assessment of intrahepatic metastases after TACE. Intralesional enhancement alone provides the most balanced diagnostic performance and reproducibility during the first 1-2 months after treatment, suggesting it may serve as a simple and reliable biomarker for early treatment response assessment. Additional perilesional and conventional US features do not improve diagnostic performance and may reduce diagnostic clarity shortly after TACE.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Xu, Liu, Wessner, et al. Feasibility of CEUS LI-RADS Nonradiation Treatment Response Assessment for Early Evaluation of Intrahepatic Metastases After TACE. Acad Radiol. 2026. PMID: 42736094. doi:10.1016/j.acra.2026.08.106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。